- Home
- BBNX vs KURA Comparison
BBNX vs KURA Comparison
Compare BBNX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBNX | KURA |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 997.9M | 1.1B |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BBNX | KURA |
|---|---|---|
| Price | $16.91 | $9.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $24.24 | ★ $31.85 |
| AVG Volume (30 Days) | 912.1K | ★ 1.6M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.95 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $100,251,000.00 | $67,482,000.00 |
| Revenue This Year | $25.74 | $42.46 |
| Revenue Next Year | $44.51 | $116.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.94 | 25.24 |
| 52 Week Low | $8.80 | $7.36 |
| 52 Week High | $32.71 | $13.90 |
Technical Indicators
Market Signals| Indicator | BBNX | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 28.29 |
| Support Level | $15.76 | $8.45 |
| Resistance Level | $18.20 | $9.82 |
| Average True Range (ATR) | 0.87 | 0.43 |
| MACD | -0.29 | -0.14 |
| Stochastic Oscillator | 24.84 | 13.52 |
Price Performance
Historical ComparisonAbout BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.